Pentavalent 99mTc DMSA: uptake into a variety of human rhabdomyosarcoma xenografts
Related Experiment Video
Updated: Oct 10, 2026
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
H Van der Wall1, D Henderson, R Baker
1Department of Nuclear Medicine, Prince of Wales Hospital, Sydney, Australia.
Background:
Rhabdomyosarcoma is a common soft tissue sarcoma of childhood. While Ga is currently the most accurate modality for imaging residual or recurrent tumour its dosimetry is unfavourable. Pentavalent 99mTc DMSA [99mTc (V) DMSA] has been shown to accumulate in this tumour in a limited number of clinical cases.
Methods:
Biodistribution of 99mTc (V) DMSA was determined in non-tumour bearing BALB-C mice. Operative specimens from four clinically 67Ga avid tumours were xenografted into nude mice and allowed to reach a significant size. Biodistribution studies were performed after the injection of 99mTc (V) DMSA in all animals and 125I HSA and 67Ga in a limited number of animals.
Results:
None of the tumours investigated demonstrated significant 99mTc (V) DMSA accumulation. Biodistribution was identical in tumour and non-tumour bearing animals.
Conclusions:
Rhabdomyo-sarcoma xenografts do not demonstrate significant uptake of 99mTc (V) DMSA.
